Companies: 10,795·Total market cap: $144.5T
Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMXNASDAQHealthcare● Active
$7.87
$-0.06(-0.76%)
Market Cap$428217930
P/E Ratio
52W High$11.61
52W Low$1.94

Immix Biopharma, Inc. (IMMX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

immx · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 4 Wall Street analysts in the past 3 months

SellBuy

Buy

4 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
4
Hold
0
Sell
0
Strong Sell
0
Total: 4 · Buy rate: 100.0%

12-Month Price Target

High

$20.00

Consensus

$17.00

+116.0% upside

Low

$14.00

Median: $17 · Last Close: $7.87

The Immix Biopharma, Inc. (IMMX) analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month IMMX price target is $17.00, representing +116.0% upside from the current price of $7.87.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $17 (116.0%)

Consensus Target

$17.00

116.0% upside

High Target

$20

154.1%

Low Target

$14

77.9%

Current Price

$7.87

as of today

Based on analyst price targets, the IMMX stock price prediction for the next 12 months ranges from $14 to $20. The consensus IMMX price forecast of $17.00 implies 116.0% upside from the current price of $7.87.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$7.485.00%

1-day model range: $7.42–$7.54. Peak: $7.54 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$8+1.1%
2028$8+1.7%
2029$8+2.0%
2030$8+2.2%
2031+2.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%0%79%
3Buy
0Neutral
11Sell
RSI (14)29.6Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · IMMX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$8.21SELL
MA 10$8.57SELL
MA 20$9.05SELL
MA 50$9.27SELL
MA 100$8.46SELL
MA 200$6.04BUY
Current $IMMX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$8.20SELL
EMA 10$8.48SELL
EMA 20$8.82SELL
EMA 50$8.96SELL
EMA 100$8.25SELL
EMA 200$6.75BUY
Current $IMMX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-22
Maintains
BuyBuy
HC Wainwright & Co.2026-03-30
Maintains
BuyBuy
Mizuho2026-03-30
Maintains
OutperformOutperform
HC Wainwright & Co.2026-03-27
Maintains
BuyBuy
Citizens2026-03-27
Maintains
Market OutperformMarket Outperform
HC Wainwright & Co.2025-12-09
Maintains
BuyBuy
HC Wainwright & Co.2025-09-12
Maintains
BuyBuy
HC Wainwright & Co.2025-06-04
Maintains
BuyBuy
HC Wainwright & Co.2025-02-10
Maintains
BuyBuy
HC Wainwright & Co.2025-01-06
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Immix Biopharma, Inc. (IMMX) stock. Of the recent 16 rating actions, 0 were upgrades and 0 were downgrades. 4 analysts currently cover IMMX.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

IMMX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$12M

↓ 94.1% YoY

Revenue Next Year

$56M

↑ 364.7% YoY

EPS This Year

$-0.70

EPS Next Year

$-0.65

↓ 7.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IMMX EPS of $-0.70 for the current fiscal year, based on estimates from 4 analysts. The IMMX revenue forecast is $12M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IMMX stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMMX price target is $17.00 (+116.0% upside), with an analyst consensus of Buy.

The IMMX short-term stock prediction for tomorrow is $7.48 (-5.00%). The IMMX stock price prediction for 2027 estimates an average of $8. The IMMX stock prediction for 2030 projects a range of $7–$9.

Immix Biopharma, Inc. trades on NASDAQ under the ticker IMMX. The IMMX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IMMX forecast · 8 questions

According to 4 Wall Street analysts, the average 12-month IMMX price target is $17.00, with a high forecast of $20.00 and a low of $14.00. The median price target is shown in the chart above when available. This implies +116.0% potential upside from the current price of $7.87.

IMMX price targetWhat is IMMX price targetIMMX analyst price targetIMMX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.